Evidence map›Paper›PMID 29261348›Full record

ArticleAJR. American journal of roentgenology2018

MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis.

Javier E Villanueva-Meyer, Matthew D Wood, Byung Se Choi, Marc C Mabray, Nicholas A Butowski, Tarik Tihan, Soonmee Cha

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AJR. American journal of roentgenology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 2 pooled it
6.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 2 syntheses or guidelines pooled it, 96 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023
    Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Javier E Villanueva-Meyer1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 350 Parnassus, 370H, San Francisco, CA 94143.
Matthew D Wood2 Department of Pathology, University of California, San Francisco, San Francisco, CA.
Byung Se Choi1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 350 Parnassus, 370H, San Francisco, CA 94143.
Marc C Mabray1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 350 Parnassus, 370H, San Francisco, CA 94143.
Nicholas A Butowski3 Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA.
Tarik Tihan2 Department of Pathology, University of California, San Francisco, San Francisco, CA.
Soonmee Cha1 Department of Radiology and Biomedical Imaging, University of California, San Francisco, 350 Parnassus, 370H, San Francisco, CA 94143.
University of California, San Francisco · US

Funding

Biomedical Imaging for Clinician ScientistsT32EB001631 · NIBIB · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI THOMAS M LINK · 2005 to 2026
$5.6M
NIBIB NIH HHS T32 EB001631
6 · The paper itself

Abstract

objectiveGrade II diffuse gliomas (DGs) with isocitrate dehydrogenase (IDH) mutations are associated with better prognosis than their IDH wild-type counterparts. We sought to determine the MRI characteristics associated with IDH mutational status and ascertain whether MRI considered in combination with IDH mutational status can better predict the clinical outcomes of grade II DGs. MATERIALS AND

methodsPreoperative MRI examinations were retrospectively studied for qualitative tumor characteristics, including location, extent, cortical involvement, margin sharpness, cystic component, mineralization or hemorrhage, and contrast enhancement. Quantitative diffusion and perfusion metrics were also assessed. Logistic regression and ROC analyses were used to evaluate the relationship between MRI features and IDH mutational status. The association between IDH mutational status, 1p19q codeletion, MRI features, extent of resection, and clinical outcomes was assessed by Kaplan-Meier and Cox proportional hazards models.

resultsOf 100 grade II DGs, 78 were IDH mutant and 22 were IDH wild type. IDH wild-type tumors were associated with older age, multifocality, brainstem involvement, lack of cystic change, and a lower apparent diffusion coefficient (ADC). Multivariable regression showed that age older than 45 years as well as low minimum ADC (ADC

conclusionIDH wild-type grade II DGs are associated with a lower ADC and poor clinical outcomes. Combining IDH mutational status and ADC may allow more accurate prediction of clinical outcomes for patients with grade II DGs.

Indexed as

AdultAge FactorsBrain NeoplasmsContrast MediaFemaleGliomaHumansIsocitrate DehydrogenaseMagnetic Resonance ImagingMaleMiddle AgedNeoplasm GradingOrganometallic CompoundsPrognosisRisk FactorsContrast MediagadobutrolIsocitrate DehydrogenaseOrganometallic Compoundsgrade II diffuse gliomasIDHisocitrate dehydrogenaselow-grade gliomaMRI

Identifiers

PMID29261348
PMCPMC5823758
OpenAlexW2781200392

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.